GPT and metabolic dysfunction-associated steatotic liver disease: A phase 2 clinical trial has indicated that 16 weeks of 4 mg Saroglitazar treatment markedly improves alanine aminotransferase (ALT) levels and insulin resistance in a cohort of 106 patients with MASLD/MASH syndrome [53].